截至8月20日收盘，重组蛋白概念下跌0.85%，位居概念板块跌幅榜前列，板块内，贝达药业、赛升药 业、热景生物等跌幅居前，股价上涨的有18只，涨幅居前的有中源协和、华熙生物、*ST万方等，分别 上涨3.27%、2.53%、2.23%。 今日涨跌幅居前的概念板块 | 688131 | 皓元医药 | 1.88 | 2.60 | 2045.37 | | --- | --- | --- | --- | --- | | 600420 | 国药现代 | 0.18 | 1.36 | 2185.08 | | 688363 | 华熙生物 | 2.53 | 1.32 | 4753.90 | | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 同花顺果指数 | 3.70 | 猴痘概念 | -0.86 | | AI手机 | 2.77 | 重组蛋白 | -0.85 | | 国家大基金持股 | 2.76 | 辅助生殖 | -0.81 | | MCU芯片 | 2.60 | 高压氧舱 | -0.68 | | 丙烯酸 | 2.56 | 肝炎概念 | -0.67 | | 智 ...

证券之星消息，8月20日医疗美容板块较上一交易日上涨3.29%，爱美客领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 188.50 | 3.96% | 6.60万 | | 12.23 Z | | 688363 | 华熙生物 | 55.17 | 2.53% | 6.35万 | | 3.46 Z | | 000615 | *ST美谷 | 3.29 | 0.92% | 8.81万 | | 2891.00万 | | 832982 | 锦波生物 | 312.89 | -0.66% | 8461.09 | | 2.65亿 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流入7610.08万元，游资资金净流入 ...

金融界消息 截至2025年8月19日收盘，华熙生物（688363）报收于53.81元，下跌0.06%，换手率 0.69%，成交量3.32万手，成交金额1.79亿元。 资金流向方面，今日主力资金净流入1079.40万元，占比成交额6.04%。其中，超大单净流入674.10万 元、占成交额3.77%，大单净流入405.30万元、占成交额2.27%，中单净流出流出439.07万元、占成交额 2.46%，小单净流出640.33万元、占成交额3.58%。 通过天眼查大数据分析，华熙生物科技股份有限公司共对外投资了31家企业，参与招投标项目414次， 知识产权方面有商标信息3893条，专利信息814条，此外企业还拥有行政许可92个。 来源：金融界 华熙生物最新一期业绩显示，截至2025一季报，公司营业总收入10.78亿元、同比减少20.77%，归属净 利润1.02亿元，同比减少58.13%，扣非净利润8190.76万元，同比减少64.62%，流动比率2.367、速动比 率1.272、资产负债率18.50%。 天眼查商业履历信息显示，华熙生物科技股份有限公司，成立于2000年，位于济南市，是一家以从事医 药制造业为主的企业 ...

证券之星消息，8月19日医疗美容板块较上一交易日下跌0.76%，爱美客领跌。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 832982 | 锦波生物 | 314.96 | 2.11% | 1.44万 | 4.53 乙 | | 000615 | *ST美谷 | 3.26 | 1.56% | 12.18万 | 3954.31万 | | 688363 | 华熙生物 | 53.81 | -0.06% | 3.32万 | 1.79亿 | | 300896 | 爱美客 | 181.32 | -1.39% | 4.85万 | 8.80亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出762.74万元，游资资金净流入884.18万元，散户资 金净流出121.45万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 │主力净流入（元）│主力净占比│游资净流入（元） ...

Market Performance - The medical beauty sector increased by 1.03% on August 18, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3728.03, up 0.85%, while the Shenzhen Component Index closed at 11835.57, up 1.73% [1] Individual Stock Performance - Jinbo Biological (832982) closed at 308.46, with a rise of 3.60% and a trading volume of 16,000 shares [1] - Aimeike (300896) closed at 183.87, up 1.09% with a trading volume of 43,400 shares [1] - Huaxi Biological (688363) closed at 53.84, increasing by 1.01% with a trading volume of 49,300 shares [1] - *ST Meigu (000615) closed at 3.21, up 0.31% with a trading volume of 107,200 shares [1] Capital Flow Analysis - The medical beauty sector experienced a net outflow of 7.81 million yuan from main funds, while retail funds saw a net outflow of 22.98 million yuan [1] - Speculative funds had a net inflow of 30.79 million yuan [1] Detailed Capital Flow for Individual Stocks - Aimeike (300896) had a main fund net inflow of 15.99 million yuan, with a retail net outflow of 34.19 million yuan [2] - *ST Meigu (000615) saw a main fund net inflow of 0.25 million yuan, with a retail net outflow of 1.13 million yuan [2] - Huaxi Biological (688363) experienced a main fund net outflow of 24.06 million yuan, while retail funds had a net inflow of 1.23 million yuan [2]

Core Insights - The article discusses the competitive landscape and market dynamics of the functional skincare industry in China, highlighting key players, market share, and industry concentration levels [1][9][11]. Group 1: Brand Ranking - The functional skincare market in China is segmented into three main categories: dermatological skincare, strong efficacy skincare, and medical aesthetic skincare, with leading brands in each category [1]. - Notable brands in dermatological skincare include Winona, La Roche-Posay, and Avene; strong efficacy brands include WIS and HFP; medical aesthetic brands include Fulejia and Aimeike [1]. Group 2: Revenue and Market Position - The functional skincare industry is divided into three tiers based on revenue: - Tier 1: Betaini with revenue exceeding 5 billion CNY, leading the market [3][12]. - Tier 2: Companies like Giant Biological, Shanghai Jahwa, and Fulejia, which have significant revenue and brand recognition [3]. - Tier 3: Companies such as Proya and Furuida, which are publicly listed but have lower revenue from functional skincare [4]. Group 3: Market Share - The projected market size for functional skincare in China for 2024 is approximately 48.743 billion CNY, with Betaini holding a market share of 11.71% [9]. - Other significant players include Huaxi Biological at 5.27%, Fulejia at 4.14%, Shanghai Jahwa at 2.15%, and Giant Biological at 2.44% [9]. Group 4: Market Concentration - The market concentration for domestic functional skincare brands is relatively low, with the top three companies accounting for 21.12% of revenue and the top six for 26.47% [11]. - There is a trend of increasing market concentration, with leading players establishing brand and research barriers [11]. Group 5: Competitive Landscape - The industry shows a strong reliance on imported raw materials, with suppliers having significant bargaining power [16]. - Domestic brands are gaining market share, and competition is intensifying, with high profit margins and potential threats from new entrants and alternative products [16].

Investment Rating - The report maintains a "Buy" rating for the high-end domestic cosmetics brand Mao Geping, projecting a net profit of 1.184 billion, 1.542 billion, and 1.953 billion yuan for 2025-2027, with year-on-year growth rates of +34%, +30%, and +27% respectively [15]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index growing by only 0.1% from August 8 to August 15, 2025, lagging behind the Shenwan A Index by 3.0 percentage points [6][7]. - Domestic brands are actively preparing for the upcoming consumption peak, with significant announcements from brands like Proya and Up Beauty, indicating a strategic focus on high-end markets [12]. - Mao Geping's performance in H1 2025 shows a strong revenue forecast of 2.57 billion to 2.6 billion yuan, reflecting a year-on-year growth of 30.4% to 31.9%, and a net profit of 665 million to 675 million yuan, indicating robust profitability in the high-end domestic makeup segment [13][14]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the overall market, with specific indices showing minimal growth [6][7]. - The top-performing stocks in the sector included Baiya Co. (+11.0%) and Nuobang Co. (+6.0%), while the worst performers were Beijia Co. (-13.1%) and Mao Geping (-9.4%) [8]. Recent Developments - The report highlights the upcoming earnings season for key domestic brands, with expectations for significant financial disclosures from companies like Runben Co. and Marubi Biological [12]. - New Oxygen Group reported a Q2 revenue of 379 million yuan, with its light medical beauty chain business showing a remarkable year-on-year growth of 426% [24][25]. E-commerce and Market Trends - The report provides insights into the e-commerce performance of domestic brands, with notable growth in GMV for brands like Proya and Up Beauty, indicating a strong online presence [18]. - The retail sales of cosmetics in July 2025 showed a year-on-year growth of 4.5%, suggesting a recovery in consumer spending [19][22]. Market Share and Competitive Landscape - The domestic cosmetics market is becoming increasingly competitive, with local brands gaining market share against international competitors, as evidenced by the performance of brands like Proya and Natural Hall [31][36]. - The report notes that the market for skincare products is projected to reach 271.2 billion yuan in 2024, despite a slight decline in growth [31].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail sector shows steady recovery with a year-on-year increase of 4.8% in total retail sales from January to July 2025, and a 3.7% increase in July alone [5][25] - Online channels continue to grow, while offline growth rates are marginally slowing down; specific categories like gold and jewelry, as well as cosmetics, show significant improvement [5][30] - The report emphasizes the importance of consumer sentiment and suggests focusing on high-growth segments such as gold jewelry and domestic beauty brands [8][34] Summary by Sections Retail Market Overview - The retail index closed at 2214.55 points, up 0.44% for the week, underperforming the Shanghai Composite Index which rose by 0.86% [7][16] - The commercial property management sector saw the highest increase this week, while the jewelry sector has led the gains since the beginning of 2025 with a 30.19% increase [20][22] Retail Sales Data - In July 2025, retail sales reached 38,780 billion yuan, with a year-on-year growth of 3.7% [25] - Online retail sales for the first seven months of 2025 reached 86,835 billion yuan, growing by 9.2% year-on-year, with physical goods online sales at 70,790 billion yuan, up 6.3% [27][28] Key Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending companies like Laopuhuangjin and Chaohongji [8][34] - **Cosmetics**: Highlighting the rise of domestic brands and the need for innovation in product offerings, with recommendations for brands like Maogeping and Pola [8][35] - **Offline Retail**: Emphasizing the transformation of retail enterprises to adapt to changing consumer behaviors, recommending companies like Yonghui Supermarket and Aiyingshi [8][34] - **Medical Aesthetics**: Suggesting investment in companies with differentiated product lines, recommending Aimeike and Kedi-B [8][36] Company Performance Highlights - Laopuhuangjin reported a revenue of 85.06 billion yuan in 2024, with a net profit increase of 253.9% [40] - Maogeping achieved a revenue of 38.85 billion yuan in FY2024, with a growth of 34.6% [36] - Yonghui Supermarket's revenue for Q1 2025 was 174.79 billion yuan, reflecting a decline of 19.3% [36]

Core Viewpoint - Huaxi Biological has successfully registered its fermentation-derived sodium chondroitin sulfate with the National Medical Products Administration, marking it as the first company in China to achieve compliance for this product [1][4] Company Announcements - Huaxi Biological's fermentation-derived sodium chondroitin sulfate has completed the main document registration for medical devices, allowing it to be used in Class II and III medical devices, potentially providing core materials for high-end medical equipment [1][4] - The controlling shareholder, Huaxi Xinyu Investment Co., Ltd., plans to increase its stake in Huaxi Biological by investing between RMB 200 million and RMB 300 million over the next six months, with a maximum purchase price of RMB 70 per share [3][4] Market Context - Traditional chondroitin sulfate is extracted from animal cartilage, which poses issues such as immunogenicity, unsustainable sourcing, and high pollution from extraction processes. The company aims to leverage synthetic biology technology to develop chondroitin sulfate raw materials for ophthalmology, orthopedics, and medical aesthetics [2]

从资金流向上来看，当日医疗美容板块主力资金净流出1.09亿元，游资资金净流入3976.24万元，散户资 金净流入6952.12万元。医疗美容板块个股资金流向见下表： 证券之星消息，8月15日医疗美容板块较上一交易日上涨0.43%，*ST美谷领涨。当日上证指数报收于 3696.77，上涨0.83%。深证成指报收于11634.67，上涨1.6%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.20 | 1.59% | 12.51万 | 4001.05万 | | 688363 | 华熙生物 | 53.30 | 1.52% | 3.30万 | 1.75 Z | | 832982 | 锦波生物 | 297.75 | 0.34% | 7423.21 | 2.20亿 | | 300896 | 爱美客 | 181.89 | -0.37% | 4.26万 | 7.72亿 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备3101043 ...